Navigation Links
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Date:4/24/2008

. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of the development of viral resistance in any dose cohort after 14 days of dosing.

In a 4-week Phase 1 combination study that was conducted in 50 treatment- naive patients chronically infected with HCV genotype 1, R7128 demonstrated potent short-term antiviral activity and was generally safe and well tolerated. Eighty-five percent (85%) of patients receiving R7128 1500mg twice- daily (BID) with Pegasys plus Copegus for 4 weeks achieved undetectable HCV RNA levels with safety and tolerability comparable to placebo with Pegasys plus Copegus.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under th
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmasset Receives $10 Million of Working Capital
3. Pharmasset Appoints Herbert J. Conrad as a Director
4. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
5. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
6. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
7. Pharmasset Reports Fiscal Year End 2007 Financial Results
8. Pharmasset Appoints Michael Rogers as Chief Development Officer
9. Pharmasset to Present at Three Investor Conferences in November 2007
10. Pharmasset Accesses up to $30 Million of Working Capital
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 The DNA ... and concise visual representation of history, migration, and culture. ... always regaled by family history stories stemming from Europe. ... the "old country." Pictures and 8mm home movies painted ... of the family, and Steve ordered a test from ...
(Date:7/22/2014)... 2014  Neogen Corporation (NASDAQ: NEOG ) ... which ended May 31, increased 19% from the previous ... compared to the prior year,s $27,190,000. Adjusted for a ... share in the current year were $0.76, compared to ... for the 2014 fiscal year established new all-time highs ...
(Date:7/22/2014)... SHENZHEN, China , 22 juli 2014 ... van BGI, ,s wereld grootste organisatie op het gebied ... nieuwe service ten behoeve van hele menselijke genoomsequentie via ... Genomics. In 2013 acquireerde BGI Complete ... aanzien staat vanwege de in eigen beheer ontwikkelde sequentietechnologieën ...
(Date:7/22/2014)... 22, 2014 In chemical and ... increasingly common sight. The rapid rise of TDL ... well- established as a core gas measurement technology, ... made them the gas analyzer technology of choice ... encountered in some processes have limited their application ...
Breaking Biology Technology:DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2METTLER TOLEDO Shows How Tunable Diode Lasers (TDLs) Can Be Installed Where No TDLs Have Gone Before 2
... , SEATTLE, Aug. 5 ... Murray, M.D., Ph.D. as Vice President of Clinical Development. ... at Omeros, and currently is leading the ongoing clinical ... the Company,s lead candidate being evaluated in a Phase ...
... The FIME 2009 ... John Rizvi will deliver a presentation titled, "Preservation of Legal Rights in Medical Innovations" at ... ... 2009 at 1:00 PM, attorney John Rizvi will deliver a presentation titled, "Preservation of Legal ...
... to develop organic solar cells that can be produced easily ... to generate electricity. But a major obstacle is coaxing ... the nanoscale (tinier than 2-millionths of an inch) to be ... to develop cells made from low-cost plastics that will transform ...
Cached Biology Technology:Omeros Appoints New Vice President of Clinical Development 2Patent Attorney John Rizvi Speaks at FIME International Medical Expo 2Plastics that convert light to electricity could have a big impact 2Plastics that convert light to electricity could have a big impact 3
(Date:7/22/2014)... of Standards and Technology (NIST), working with the ... for analyzing biological cells and tissues based on ... is an advanced form of the widely used ... that are 10,000 times stronger than obtained from ... obtained from comparable "coherent Raman" instruments, and uses ...
(Date:7/22/2014)... as disease causing agents, some viruses can perform ... shape the world we live in today, according ... of Microbiology. , "Viruses participate in essential Earth ... planet, from contributing to biogeochemical cycles, shaping the ... Marilyn Roossinck of Pennsylvania State University, a member ...
(Date:7/22/2014)... Stem cells offer much promise for treating damaged organs ... survival is poor, limiting their effectiveness. New methods are ... optimize their therapeutic function after transplantation, as described in ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Open Access website . , In ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
... key to the blinding effects of diabetic retinopathy is ... Georgia researchers said. Interleukin-6, known to contribute ... helps ignite inflammation of the retina, a first step ... blindness is working-age adults, MCG researchers reported online in ...
... of dollars each year on exotic smelling perfumes and lotions ... a new study in Psychological Science , a journal ... be the best way to capture a potential mate,s attention. ... habits: Animal studies have shown that male testosterone levels are ...
... Malaga have created the ,Inventory of Daily Stressors, a ... physical appearance, taking part in numerous extracurricular activities and ... that increase the risk of suffering from childhood stress. ... to assess daily stress amongst schoolchildren", Mara Victoria Trianes, ...
Cached Biology News:Discovery points toward anti-inflammation treatment for blinding disease 2A new method to measure childhood stress 2